These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 24979148)

  • 1. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.
    Vijan S; Sussman JB; Yudkin JS; Hayward RA
    JAMA Intern Med; 2014 Aug; 174(8):1227-34. PubMed ID: 24979148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.
    Laiteerapong N; Cooper JM; Skandari MR; Clarke PM; Winn AN; Naylor RN; Huang ES
    Ann Intern Med; 2018 Feb; 168(3):170-178. PubMed ID: 29230472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes.
    Lipska KJ; Krumholz H; Soones T; Lee SJ
    JAMA; 2016 Mar; 315(10):1034-45. PubMed ID: 26954412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.
    Roze S; Duteil E; Smith-Palmer J; de Portu S; Valentine W; de Brouwer BF; Reznik Y; de Valk HW
    J Med Econ; 2016 Aug; 19(8):742-9. PubMed ID: 26985982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.
    Hayward RA; Manning WG; Kaplan SH; Wagner EH; Greenfield S
    JAMA; 1997 Nov; 278(20):1663-9. PubMed ID: 9388085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line agents for glycemic control for type 2 diabetes: are newer agents better?
    Zhang Y; McCoy RG; Mason JE; Smith SA; Shah ND; Denton BT
    Diabetes Care; 2014; 37(5):1338-45. PubMed ID: 24574345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Targeted Insulin-Adherence Interventions for Glycemic Control Using Predictive Analytics Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Lauffenburger JC; Lewey J; Jan S; Makanji S; Ferro CA; Krumme AA; Lee J; Ghazinouri R; Haff N; Choudhry NK
    JAMA Netw Open; 2019 Mar; 2(3):e190657. PubMed ID: 30874782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Be Careful What You Ask For: Effects of Benefit Descriptions on Diabetes Patients' Benefit-Risk Tradeoff Preferences.
    von Arx LB; Johnson FR; Mørkbak MR; Kjær T
    Value Health; 2017 Apr; 20(4):670-678. PubMed ID: 28408010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Ray JA; Valentine WJ; Roze S; Nicklasson L; Cobden D; Raskin P; Garber A; Palmer AJ
    Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing potential glycemic overtreatment in persons at hypoglycemic risk.
    Tseng CL; Soroka O; Maney M; Aron DC; Pogach LM
    JAMA Intern Med; 2014 Feb; 174(2):259-68. PubMed ID: 24322626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
    Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2539-2546. PubMed ID: 34158243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
    Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
    Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.